Effects of One-to-one Service on the Continuation and Satisfaction of Contraceptive Use.

Sponsor
National Research Institute for Family Planning, China (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05362019
Collaborator
(none)
400
8
2
10
50
5

Study Details

Study Description

Brief Summary

This study aims to explore the impact of a mobile based one-to-one service model on improving the continuation and satisfaction of combined injectable contraceptive use, and improve the utilization and acceptability of efficient and long-term contraceptive methods.

Condition or Disease Intervention/Treatment Phase
  • Drug: Compound Norethisterone Enanthate Injection
  • Other: One-to-one Service
  • Other: Family Planning Service
N/A

Detailed Description

In China, due to the lack of understanding or misunderstanding of hormonal contraception by service providers and the public, the use of combined injectable contraceptive is not common. Therefore, this study aims to explore the impact of a mobile based one-to-one service model on improving the continuation and satisfaction of combined injectable contraceptive use, and improve the utilization and acceptability of efficient and long-term contraceptive methods.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
400 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
Effects of One-to-one Service on the Continuation and Satisfaction of Combined Injectable Contraceptive Use.
Anticipated Study Start Date :
May 1, 2022
Anticipated Primary Completion Date :
Dec 1, 2022
Anticipated Study Completion Date :
Mar 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: intervention group

A mobile phone based "service system" developed by the research group will be used to provide one-to-one service for the intervention group.

Drug: Compound Norethisterone Enanthate Injection
Combined injectable contraceptive use

Other: One-to-one Service
A mobile phone based "service system" will be used to pushing contraceptive knowledges, reminding injection, providing consultation on adverse reactions and ect.

Active Comparator: control group

Routine family planning services will be provided to the control group.

Drug: Compound Norethisterone Enanthate Injection
Combined injectable contraceptive use

Other: Family Planning Service
routine family planning service and contraceptive service.

Outcome Measures

Primary Outcome Measures

  1. Termination rate [6 months]

    The termination rates of the two groups were observed for 6 months.

  2. Continuation rate [6 months]

    The continuation rates of the two groups were observed for 6 months.

  3. Satisfaction rates [Up to 4 weeks]

    The satisfaction rates of two groups after a 6 months of contraceptive use.

Secondary Outcome Measures

  1. Complaint of adverse reactions [Up to 9 months]

    Complaint rates of various adverse reactions (dizziness / breast swelling / nausea) during different follow-up time.

  2. Vaginal bleeding pattern [Up to 9 months]

    Collecting the vaginal bleeding patterns (including menstrual onset time, duration, and termination time) in two phases (90 days in each phase) and amount of menstrual bleeding at 3 months of use by using a self-developed questionnarie and special sanitary pads for measurement.

  3. Dysmenorrhea [Up to 9 months]

    Dysmenorrhea will be collacted by a self-developed questionnarie (on a 10-point scale). A higher score indicated higher level of pain.

  4. Waist and abdomen pain related to gynecology [Up to 9 months]

    The pain will be collacted by a self-developed questionnarie (on a 10-point scale). A higher score indicated higher level of pain.

  5. Sexual intercourse pain [Up to 9 months]

    The pain will be collacted by a self-developed questionnarie (on a 10-point scale). A higher score indicated higher level of pain.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 40 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • 18 to 40 years old;

  • Healthy Volunteers;

  • More than 6 months after delivery and without lactation;

  • No fertility intention within 6 months;

  • Normal menstruation;

  • No contraindications to the use of compound contraceptive methods;

  • Had not used hormonal contraception in the previous three months;

  • Understand the content and requirements of the project, be willing to cooperate, and have signed the informed consent form;

  • Have a certian education level, and be able to use the special sanitary napkins to record menstrual volume and menstrual card.

Exclusion Criteria:
  • Suffering from serious systemic diseases;

  • Previous or current thrombotic disease;

  • Malignant tumor of uterine organ;

  • Unable to communicate normally due to disability or mental or intellectual impairment.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Qinghai People's Hospital Xining Qinghai China
2 Qinghai Red Cross Hospital Xining Qinghai China
3 Tianjin Central Hospital of Gynecology Obstetrics Tianjin Tianjin China
4 Tianjin Dongli hospital Tianjin Tianjin China
5 Tianjin Jinnan hospital Tianjin Tianjin China
6 Tianjin Medical University second hospital Tianjin Tianjin China
7 Yunnan Xishuangbanna maternal and Child Health Hospital Xishuangbanna Yunnan China
8 Yunnan Xishuangbanna people's Hospital Xishuangbanna Yunnan China

Sponsors and Collaborators

  • National Research Institute for Family Planning, China

Investigators

  • Principal Investigator: Kaiyan Pei, National Research Institute for Family Planning, China

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
National Research Institute for Family Planning, China
ClinicalTrials.gov Identifier:
NCT05362019
Other Study ID Numbers:
  • 2021HX019
First Posted:
May 5, 2022
Last Update Posted:
May 5, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 5, 2022